Anvisa Approves Generic Medicines Against Diabetes and Obesity
17 Articles
17 Articles
Freepik The National Agency for Health Surveillance (Anvisa) approved two new generic liraglutide-based medicines, an active principle used in pens for the treatment of obesity and type 2 diabetes. The authorisations were granted to the Brazilian pharmacist EMS. The products will have a concentration of 6 mg/mL, in solution for injection of subcutaneous application. The two pens are linked to medicines that EMS itself already markets: Olire, ind…
Records allow two liraglutide 6 mg/mL pens to be sold by the active principle name to treat obesity and type 2 diabetes.
Medicines are generic of liraglutide and may cost 35% less
divulgation Olire and Lirux: new records are linked to drugs already marketed by EMS Photo: Disclosure The National Agency for Health Surveillance (Anvisa) approved the registration of two more generic drugs based on liraglutide, an active principle used in pens to treat obesity and type 2 diabetes.The pharmaceuticals responsible for the drugs is EMS and the approved versions are injectable, of subcutaneous use, with a concentration of 6 mg/ml.T…
Semaglutida gained generics, while liraglutida had 2 new versions approved by Anvisa on 3rd Friday. Read on Power360.
EBC
The National Agency for Health Surveillance (Anvisa) approved the records of two generic drugs based on liraglutide. The substance is used in pens to treat obesity and type 2 diabetes. Both will have a concentration of 6 mg/mL. The authorizations were granted to the Brazilian pharmacist EMS and published on Tuesday (8) in the Official Journal of the Union. The company already markets two pens with the medicines: Olire, focused on weight control …
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
